New malaria vaccine effective in clinical trial
Tübingen researchers achieve protection of up to 100 percent using fully viable malaria parasites
Tübingen researchers have demonstrated in a clinical trial that a new vaccine for malaria called Sanaria® PfSPZ-CVac has been up to 100 percent effective when assessed at 10 weeks after last dose of vaccine. The vaccine incorporated fully viable – not weakened or otherwise inactivated – malaria pathogens together with the medication to combat them. Malaria parasites are transmitted by the bite of female Anopheles mosquitoes. The Plasmodium falciparum parasite is responsible for most malaria infections and almost all deaths caused by the disease worldwide. Most of the previous vaccines which have been tried involved the use of individual molecules found in the pathogen. However, they were unable to provide sufficient immunity to the disease.